These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28723952)

  • 21. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century.
    Lesage S; Leutenegger AL; Ibanez P; Janin S; Lohmann E; Dürr A; Brice A;
    Am J Hum Genet; 2005 Aug; 77(2):330-2. PubMed ID: 16145815
    [No Abstract]   [Full Text] [Related]  

  • 22. Using KASP technique to screen LRRK2 G2019S mutation in a large Tunisian cohort.
    Landoulsi Z; Benromdhan S; Ben Djebara M; Damak M; Dallali H; Kefi R; Abdelhak S; Gargouri-Berrechid A; Mhiri C; Gouider R
    BMC Med Genet; 2017 Jul; 18(1):70. PubMed ID: 28683740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
    Kim J; Daadi MM
    Brain Res; 2019 Nov; 1722():146342. PubMed ID: 31330122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 G2019S Parkinson's disease with more benign phenotype than idiopathic.
    Ben Romdhan S; Farhat N; Nasri A; Lesage S; Hdiji O; Ben Djebara M; Landoulsi Z; Stevanin G; Brice A; Damak M; Gouider R; Mhiri C
    Acta Neurol Scand; 2018 Nov; 138(5):425-431. PubMed ID: 29989150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
    Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
    JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from southern Italy.
    Criscuolo C; De Rosa A; Guacci A; Simons EJ; Breedveld GJ; Peluso S; Volpe G; Filla A; Oostra BA; Bonifati V; De Michele G
    Mov Disord; 2011 Aug; 26(9):1733-6. PubMed ID: 21538529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
    Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
    Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease.
    Zabetian CP; Morino H; Ujike H; Yamamoto M; Oda M; Maruyama H; Izumi Y; Kaji R; Griffith A; Leis BC; Roberts JW; Yearout D; Samii A; Kawakami H
    Neurology; 2006 Aug; 67(4):697-9. PubMed ID: 16728648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LRRK2 mutations are a common cause of Parkinson's disease in Spain.
    Mata IF; Ross OA; Kachergus J; Huerta C; Ribacoba R; Moris G; Blazquez M; Guisasola LM; Salvador C; Martinez C; Farrer M; Alvarez V
    Eur J Neurol; 2006 Apr; 13(4):391-4. PubMed ID: 16643318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
    Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
    Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 G2019S founder haplotype in the Chinese population.
    Tan EK; Skipper L; Tan L; Liu JJ
    Mov Disord; 2007 Jan; 22(1):105-7. PubMed ID: 17083102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
    De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
    J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease.
    Funalot B; Nichols WC; Pérez-Tur J; Mercier G; Lucotte G
    Genet Test; 2006; 10(4):290-3. PubMed ID: 17253937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.